Close Menu

NEW YORK – OpGen said Thursday that its subsidiary Curetis will have access to an additional €5 million ($5.65 million) debt financing tranche that it plans to use for research and development activities related to the COVID-19 pandemic.

The debt financing facility was originally placed in 2016 and amended in 2019, and the additional €5 million will be used to co-fund R&D programs related to COVID-19 across "several of the platforms and the entire product portfolio" of Curetis and Ares Genetics, another subsidiary of OpGen, the company said in a statement. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.